#USA #New York #Pomerantz Law Firm #VYKAT XR #Soleno Therapeutics

Pomerantz Law Firm Investigates Soleno Therapeutics, Inc.

In a recent development that has caught the attention of investors, Pomerantz LLP is taking a closer look at claims surrounding Soleno Therapeutics, Inc. (NASDAQ: SLNO). This investigation is particularly relevant for investors who may have been impacted by the company's fluctuating stock prices following alarming reports related to its flagship product, Vykat XR.

Background of the Investigation

The firm is delving into whether Soleno and some of its officers or directors may have participated in securities fraud or engaged in other illicit business practices. On August 15, 2025, a report published by Scorpion Capital alleged that Vykat XR was overpriced and posed safety risks for children. This revelation led to a significant stock price drop, with shares falling by $5.73 (approximately 7.41%) to close at $71.63 that same day.

The situation worsened for the company when it disclosed during its quarterly earnings call on November 4, 2025, that the discontinuation rate of Vykat XR linked to adverse effects was around 8% by the end of the third quarter of fiscal 2025. The Chief Executive Officer admitted there was a marked disruption in the Vykat XR launch trajectory in light of the Scorpion report, noting it contributed to fewer start forms and an increase in discontinuations due to non-serious adverse events. Following this news, Soleno's stock price plummeted further, decreasing by $16.98 (approximately 26.59%) to close at $46.87 on November 5, 2025.

The Role of Pomerantz LLP

Pomerantz LLP, renowned for its expertise in corporate and securities class litigation, has a storied history of advocating for victims of securities fraud and corporate malpractice. Founded by the esteemed Abraham L. Pomerantz, known as the dean of the class action bar, the firm has built a reputation for recovering significant damages on behalf of investors. Their commitment to upholding the rights of investors exemplifies their practice.

Given the troubling developments surrounding Soleno, Pomerantz encourages affected investors to reach out for more information. Investors can contact Danielle Peyton via email at [email protected] or by phone at 646-581-9980, ext. 7980.

This investigation into Soleno Therapeutics highlights the broader implications for investors involved in companies facing allegations of business misconduct. It serves as a reminder of the need for transparency and accountability from corporate leaders, and the potential repercussions of failing to uphold these standards. As the landscape of securities laws and regulations continues to evolve, such investigations play a vital role in protecting investors and ensuring that companies adhere to ethical practices.

Contact Information

For more details about the investigation or to participate in the potential class action, investors are urged to reach out to Pomerantz LLP. The firm operates in various major cities, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, reflecting its global reach and commitment to advocating for investor rights across geographies.

As the story unfolds, more information will be made available, and investors should remain vigilant about the ongoing developments related to Soleno Therapeutics.